Adawi Kamal
- SEC CIK
- 0001788393
No open-market purchases or sales filed in the past year.
Current role at each company
- FATE Fate Therapeutics IncChief Financial Officeras of Jan 16, 2026
- XGN Exagen Inc.CFO and Corporate Secretaryas of Mar 6, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Adawi Kamal as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
XGN Exagen Inc.
CFO and Corporate Secretary4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Adawi KamalCFO and Corporate Secretary | SSale | −12.8K | $1.91 | −$24.4K | −5.0%243.7K after | 2 lots |
| Feb 8, 2024 (view filing) | Feb 6 | 2 days | Adawi KamalCFO and Corporate Secretary | SSale | −6.74K | $1.95 | −$13.1K | −3.6%181.5K after | |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Adawi KamalCFO and Corporate Secretary | SSale | −3.67K | $2.30 | −$8.43K | −1.9%188.3K after | |
| Feb 10, 2023 (view filing) | Feb 8 | 2 days | Adawi KamalCFO and Corporate Secretary | SSale | −5.82K | $2.69 | −$15.7K | −6.0%91.9K after |